Publications
Detailed Information
Effect of the combination of mitiglinide and metformin on glycemic control in patients with type 2 diabetes mellitus
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Young Min | - |
dc.contributor.author | Koo, Bo Kyung | - |
dc.contributor.author | Son, Ho Young | - |
dc.contributor.author | Lee, Kwang Woo | - |
dc.contributor.author | Choi, Dong Seop | - |
dc.contributor.author | Kim, Yong Ki | - |
dc.contributor.author | Lee, Hyun Chul | - |
dc.contributor.author | Chung, Min Young | - |
dc.contributor.author | Kim, Youngkun | - |
dc.contributor.author | Lee, Hong Kyu | - |
dc.contributor.author | Park, Kyong Soo | - |
dc.contributor.author | Yoo, Hyung Joon | - |
dc.contributor.author | Baek, Hong Sun | - |
dc.contributor.author | Min, Kyung Wan | - |
dc.contributor.author | Lee, Moon Kyu | - |
dc.contributor.author | Kim, Bo Wan | - |
dc.contributor.author | Son, Hyun Shik | - |
dc.date.accessioned | 2012-06-26T06:33:39Z | - |
dc.date.available | 2012-06-26T06:33:39Z | - |
dc.date.issued | 2010-08 | - |
dc.identifier.citation | JOURNAL OF DIABETES INVESTIGATION; Vol.1 4; 143-148 | ko_KR |
dc.identifier.issn | 2040-1116 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77461 | - |
dc.description.abstract | Aims/Introduction: Mitiglinide is the newest drug in the meglitinide family. It increases the early-phase insulin release through rapid association-dissociation kinetics in the pancreatic beta cells. The efficacy and safety of adding meglitinide to metformin monotherapy in patients with type 2 diabetes are unknown. Materials and Methods: We carried out a prospective, randomized, multicenter trial to assess the efficacy and safety of combined treatment with mitiglinide and metformin for patients with type 2 diabetes who showed inadequate glycemic control with metformin monotherapy. Subjects with glycated hemoglobin (HbA(1c)) > 7.0% after an 8-week metformin run-in phase were randomized to a 16-week trial phase with metformin plus mitiglinide (Met + Mit) or metformin plus placebo (Met + Pcb). Results: Compared with the Met + Pcb group, the Met + Mit group showed a greater reduction in HbA(1c) (-0.7 +/- 0.6% vs -0.4 +/- 0.7%, P = 0.002), fasting plasma glucose (-0.77 +/- 1.76 mmol/L vs -0.05 +/- 1.60 mmol/L, P = 0.015) and 2-h postprandial glucose (-3.76 +/- 3.57 mmol/L vs -0.84 +/- 3.07 mmol/L, P < 0.0001). The proportion of the patients who achieved the target HbA(1c) value of < 7% at the end of the study was also higher in the Met + Mit group than the Met + Pcb group (49.3% vs 28.8%, P = 0.016). There were no differences in the adverse event rates between groups. Conclusions: Combination therapy with metformin and mitiglinide is effective and safe for the treatment of patients with type 2 diabetes who have inadequate glycemic control with metformin monotherapy. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2010.00023.x, 2010) | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | WILEY-BLACKWELL | ko_KR |
dc.subject | Mitiglinide | ko_KR |
dc.subject | Metformin | ko_KR |
dc.subject | Type 2 diabetes | ko_KR |
dc.title | Effect of the combination of mitiglinide and metformin on glycemic control in patients with type 2 diabetes mellitus | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 조영민 | - |
dc.contributor.AlternativeAuthor | 구보경 | - |
dc.contributor.AlternativeAuthor | 손호영 | - |
dc.contributor.AlternativeAuthor | 이광우 | - |
dc.contributor.AlternativeAuthor | 손현식 | - |
dc.contributor.AlternativeAuthor | 최동섭 | - |
dc.contributor.AlternativeAuthor | 김보완 | - |
dc.contributor.AlternativeAuthor | 김용기 | - |
dc.contributor.AlternativeAuthor | 이문규 | - |
dc.contributor.AlternativeAuthor | 이현철 | - |
dc.contributor.AlternativeAuthor | 민경완 | - |
dc.contributor.AlternativeAuthor | 정민영 | - |
dc.contributor.AlternativeAuthor | 백홍선 | - |
dc.contributor.AlternativeAuthor | 김영근 | - |
dc.contributor.AlternativeAuthor | 유형준 | - |
dc.contributor.AlternativeAuthor | 박경수 | - |
dc.contributor.AlternativeAuthor | 이홍규 | - |
dc.identifier.doi | 10.1111/j.2040-1124.2010.00023.x | - |
dc.citation.journaltitle | JOURNAL OF DIABETES INVESTIGATION | - |
dc.description.citedreference | Kaku K, 2009, ENDOCR J, V56, P739, DOI 10.1507/endocrj.K09E-023 | - |
dc.description.citedreference | Bolen S, 2007, ANN INTERN MED, V147, P386 | - |
dc.description.citedreference | Ogawa K, 2007, INT HEART J, V48, P337 | - |
dc.description.citedreference | Kumashiro N, 2007, ENDOCR J, V54, P163 | - |
dc.description.citedreference | Yoshihara T, 2006, ENDOCR J, V53, P67 | - |
dc.description.citedreference | Assaloni R, 2005, DIABETOLOGIA, V48, P1919, DOI 10.1007/s00125-005-1849-5 | - |
dc.description.citedreference | Stumvoll M, 2005, LANCET, V365, P1333 | - |
dc.description.citedreference | Leiter LA, 2005, CLIN THER, V27, pS42, DOI 10.1016/j.clinthera.2005.11.020 | - |
dc.description.citedreference | Nakagami T, 2004, DIABETOLOGIA, V47, P385, DOI 10.1007/s00125-004-1334-6 | - |
dc.description.citedreference | Raskin P, 2003, DIABETES CARE, V26, P2063 | - |
dc.description.citedreference | Del Prato S, 2003, DIABETOLOGIA, V46, pM2, DOI 10.1007/s00125-002-0930-6 | - |
dc.description.citedreference | Musi N, 2002, DIABETES, V51, P2074 | - |
dc.description.citedreference | Wright A, 2002, DIABETES CARE, V25, P330 | - |
dc.description.citedreference | MARRE M, 2002, DIABETES OBES METAB, V4, P177 | - |
dc.description.citedreference | Bonora E, 2001, DIABETOLOGIA, V44, P2107 | - |
dc.description.citedreference | Sunaga Y, 2001, EUR J PHARMACOL, V431, P119 | - |
dc.description.citedreference | Zhou GC, 2001, J CLIN INVEST, V108, P1167 | - |
dc.description.citedreference | Reimann F, 2001, BRIT J PHARMACOL, V132, P1542 | - |
dc.description.citedreference | de Souza CJ, 2001, DIABETES OBES METAB, V3, P85 | - |
dc.description.citedreference | HU S, 2001, INT J EXP DIABETES R, V2, P63 | - |
dc.description.citedreference | Horton ES, 2000, DIABETES CARE, V23, P1660 | - |
dc.description.citedreference | Hu SL, 2000, J PHARMACOL EXP THER, V293, P444 | - |
dc.description.citedreference | Laghmich A, 1999, PHARMACOL RES, V40, P475 | - |
dc.description.citedreference | Louchami K, 1999, PHARMACOL RES, V40, P297 | - |
dc.description.citedreference | Moses R, 1999, DIABETES CARE, V22, P119 | - |
dc.description.citedreference | Laghmich A, 1998, EUR J PHARMACOL, V348, P265 | - |
dc.description.citedreference | TURNER NC, 1998, PROG DRUG RES, V51, P33 | - |
dc.description.citedreference | Bailey CJ, 1996, NEW ENGL J MED, V334, P574 | - |
dc.description.citedreference | TURNER RC, 1995, DIABETES, V44, P1249 | - |
dc.description.citedreference | MALAISSE WJ, 1995, GEN PHARMACOL, V26, P1313 | - |
dc.description.citedreference | STUMVOLL M, 1995, NEW ENGL J MED, V333, P550 | - |
dc.description.citedreference | OHNOTA H, 1994, J PHARMACOL EXP THER, V269, P489 | - |
dc.description.citedreference | BAKKALINADI A, 1994, DIABETES RES, V27, P61 | - |
dc.description.citedreference | DEFRONZO RA, 1992, DIABETES CARE, V15, P318 | - |
dc.description.citedreference | CONSOLI A, 1989, DIABETES, V38, P550 | - |
dc.description.citedreference | EFENDIC S, 1984, ENDOCR REV, V5, P395 | - |
dc.description.citedreference | STEINER KE, 1982, DIABETES, V31, P964 | - |
dc.description.citedreference | CERASI E, 1967, DIABETES, V16, P615 | - |
dc.description.tc | 0 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.